DZ2519A1 - Compositions pharmaceutiques comprenant un sensibilisant à l'insuline et un agent antihyperglycémique pour une méthode de traitement du diabéte. - Google Patents

Compositions pharmaceutiques comprenant un sensibilisant à l'insuline et un agent antihyperglycémique pour une méthode de traitement du diabéte.

Info

Publication number
DZ2519A1
DZ2519A1 DZ980129A DZ980129A DZ2519A1 DZ 2519 A1 DZ2519 A1 DZ 2519A1 DZ 980129 A DZ980129 A DZ 980129A DZ 980129 A DZ980129 A DZ 980129A DZ 2519 A1 DZ2519 A1 DZ 2519A1
Authority
DZ
Algeria
Prior art keywords
pharmaceutical compositions
treating diabetes
insulin sensitizer
antihyperglycemic agent
antihyperglycemic
Prior art date
Application number
DZ980129A
Other languages
English (en)
French (fr)
Inventor
Stephen Alistair Smith
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9712865.6A external-priority patent/GB9712865D0/en
Priority claimed from GBGB9806708.5A external-priority patent/GB9806708D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Application granted granted Critical
Publication of DZ2519A1 publication Critical patent/DZ2519A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Fodder In General (AREA)
DZ980129A 1997-06-18 1998-06-17 Compositions pharmaceutiques comprenant un sensibilisant à l'insuline et un agent antihyperglycémique pour une méthode de traitement du diabéte. DZ2519A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9712865.6A GB9712865D0 (en) 1997-06-18 1997-06-18 Novel method of treatment
GBGB9806708.5A GB9806708D0 (en) 1998-03-27 1998-03-27 Novel method

Publications (1)

Publication Number Publication Date
DZ2519A1 true DZ2519A1 (fr) 2003-02-01

Family

ID=26311746

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ980129A DZ2519A1 (fr) 1997-06-18 1998-06-17 Compositions pharmaceutiques comprenant un sensibilisant à l'insuline et un agent antihyperglycémique pour une méthode de traitement du diabéte.

Country Status (24)

Country Link
EP (1) EP0975343A1 (xx)
JP (1) JP2001523271A (xx)
KR (1) KR20010013845A (xx)
CN (1) CN1274282A (xx)
AP (1) AP9901720A0 (xx)
AR (2) AR013352A1 (xx)
AU (1) AU8799998A (xx)
BG (1) BG103966A (xx)
BR (1) BR9810186A (xx)
CA (1) CA2294134A1 (xx)
CO (1) CO4940453A1 (xx)
DZ (1) DZ2519A1 (xx)
EA (1) EA200000040A1 (xx)
IL (1) IL133138A0 (xx)
MA (1) MA26510A1 (xx)
NO (1) NO996270L (xx)
NZ (1) NZ501345A (xx)
OA (1) OA11631A (xx)
PE (1) PE89199A1 (xx)
PL (1) PL337577A1 (xx)
SK (1) SK179499A3 (xx)
TR (1) TR199903072T2 (xx)
UY (1) UY25051A1 (xx)
WO (1) WO1998057635A1 (xx)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200103061T2 (tr) 1999-04-23 2002-05-21 Smithkline Beecham P.L.C. Yeni farmasötik madde.
WO2002080936A1 (en) 2001-04-04 2002-10-17 Ortho Mcneil Pharmaceutical, Inc. Combination therapy comprising glucose reabsorption inhibitors and ppar modulators
JP4590158B2 (ja) 2001-04-04 2010-12-01 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド グルコース再吸収阻害剤およびレチノイド−ｘ受容体モジュレーターを含んで成る併用療法
FR2832930A1 (fr) * 2001-12-03 2003-06-06 Lipha Composition pharmaceutique comprenant un inhibiteur d'alpha-glucosidase et un derive de thiazolidinedione et son utilisation pour la preparation de medicaments destines a traiter le diabete
JP2004067575A (ja) * 2002-08-06 2004-03-04 Yaizu Suisankagaku Industry Co Ltd 糖尿病治療薬効果促進剤
CN101121004B (zh) * 2006-08-08 2010-07-21 鲁南制药集团股份有限公司 含有胰岛素增敏剂和米格列醇的药物组合物
CN101584705B (zh) * 2008-05-24 2010-10-27 鲁南制药集团股份有限公司 一种治疗糖尿病及其并发症的药物组合物
CN101584688B (zh) * 2008-05-24 2010-11-10 鲁南制药集团股份有限公司 一种治疗糖尿病及其并发症的药物组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5900435A (en) * 1991-08-26 1999-05-04 Pharmacia & Upjohn Company Composition, food product and uses of 3-guanidinopropionic acid
US5917052A (en) * 1994-09-28 1999-06-29 Shaman Pharmaceuticals, Inc. Hypoglycemic agent from cryptolepis
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes

Also Published As

Publication number Publication date
AU8799998A (en) 1999-01-04
WO1998057635A1 (en) 1998-12-23
AR014881A1 (es) 2001-04-11
JP2001523271A (ja) 2001-11-20
IL133138A0 (en) 2001-03-19
BR9810186A (pt) 2000-08-08
UY25051A1 (es) 2000-09-29
EP0975343A1 (en) 2000-02-02
CN1274282A (zh) 2000-11-22
MA26510A1 (fr) 2004-12-20
PE89199A1 (es) 1999-10-23
NO996270D0 (no) 1999-12-17
NO996270L (no) 1999-12-17
CA2294134A1 (en) 1998-12-23
AR013352A1 (es) 2000-12-27
OA11631A (en) 2004-11-22
BG103966A (bg) 2000-07-31
KR20010013845A (ko) 2001-02-26
TR199903072T2 (xx) 2000-07-21
NZ501345A (en) 2001-10-26
PL337577A1 (en) 2000-08-28
CO4940453A1 (es) 2000-07-24
AP9901720A0 (en) 1999-12-31
SK179499A3 (en) 2000-11-07
EA200000040A1 (ru) 2000-08-28

Similar Documents

Publication Publication Date Title
DZ2520A1 (fr) Composition pharmaceutique pour une méthode de traitement du diabète sucré.
DZ2519A1 (fr) Compositions pharmaceutiques comprenant un sensibilisant à l'insuline et un agent antihyperglycémique pour une méthode de traitement du diabéte.
FR2714505B1 (fr) Dispositif et procédé pour générer une image destinée à un traitement graphique d'ordinateur tridimensionnel.
DZ2539A1 (fr) Compositions pharmaceutiques pour le traitement dela résistance à l'insuline.
NO973489D0 (no) Stabilisert gassemulsjon inneholdende fosfolipid til kontrastforbedring ved ultralydundersökelser
TNSN96104A1 (fr) Trihydrate de metahensulfonate de (1s,2s)-1-(4-hydroxyphenyl) -2-(4-hydroxy-4-phenylpiperidine-1-yl)-1-propanol et composition pharmaceutique le contenant
MX9703380A (es) Un sistema de computacion para el gerenciamiento de datos y un metodo para operar dicho sistema y, mas particularmente, un sistema de operacion de titulos automatizados (citi-cats-os).
FR2707788B1 (fr) Procédé et appareil pour réduire les discontinuités dans un système d'affichage à adressage actif.
DZ2521A1 (fr) Compositions pharmaceutiques comprenant de la 5-Ä4-Ä2-(méthyl-n-(2-pyridyl)amino)éthoxyÜbenzylÜ-thiazolidine-2,4-dione et de l'insuline pour une méthode de traitement.
FR2716075B1 (fr) Procédé pour renforcer l'efficacité d'un produit chimique agricole, renforçateur et composition de renforçateur utilisés dans ce procédé et composition chimique agricole comprenant ce renforçateur.
DE69003638D1 (de) Entwickler fuer statische ladungsbilder.
DZ2522A1 (fr) Composition comprenant un sensibilisant à l'insuline et secrétagogue d'insuline pour une méthode de traitement.
FR2717000B1 (fr) Dispositif périphérique à clavier et écran pour ordinateur.
MA21586A1 (fr) Procede de preparition d'une nouvelle forme pharmaceutique a liberation prolongee comprenant un complexe resine principe actif.
DE69625315D1 (de) Lichtempfindliche Silberhalogenid-Emulsionen und Verfahren zu ihrer Herstellung
FR2643474B1 (fr) Dispositif pour enregistrer un historique d'execution dans une unite de traitement de l'information
FR2737028B1 (fr) Architecture d'habillage d'applications pour une plate-forme informatique
MA26522A1 (fr) Composition pharmaceutique pour le traitement du diabete sucre et d'etats associes.
HUP0003626A2 (hu) Gyógyszerkészítmény diabetes kezelésére dioxo-tiazolidinnel, inzulin secretagogummal és alfa-glükozidáz inhibitorral
FR2701892B1 (fr) Procede et dispositif d'execution d'etapes de travail dans un cylindre d'une machine a imprimer.
FR2848454B1 (fr) Composition pharmaceutique comprenant une association de calcitriol et d'un corticosteroide
ITRM940776A0 (it) Apparecchio di formazione di immagini per rivelare otticamente la quantita' di un agente di sviluppo
EP0666501A3 (en) Hardening developer for silver halide photography and development method.
MA26758A1 (fr) Composition nouvelle, a liberation modifiee, pour le traitement du diabete.
TNSN97191A1 (fr) Dimesylate de cis-1-(3 ethoxyphenyl)-1-(4-phenyl-piperazine-1- yl)-4- methylcyclohexane, procede pour sa preparation et composition pharmaceutique.